Project Grant R01AR086382
Award Date 9/1/25
Completion Date 8/31/28
Dollars Obligated $1.7M
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Rochester, NY 14642, USA
Similar Awards
- This Project Grant award of $522,714 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to investigate the role of stretch activation in mammalian skeletal muscle endurance. The research will focus on measuring the characteristics and mechanisms of stretch activation in mouse slow-twitch and fast-twitch muscle fibers, including determining the specific myosin...
- The University of Rochester was awarded a $464,315 Project Grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846). The purpose of this 5-year project, beginning on July 1, 2025, is to investigate the role of the L-type Ca2+ channel Cav1.2 in the development of Achilles tendinopathy. The research aims to identify early mediators in tendons in response to...
- This Project Grant award of $719,758 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research on the role of nuclear myotubularin (MTM1) in muscle development and the pathogenesis of X-linked myotubular myopathy (XLMTM). The research aims to characterize the localization and interactome of nuclear MTM1, define alterations in nuclear structure and genome...
- This federal Project Grant award of $471,513 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research to investigate the mechanisms underlying neuromuscular diseases where glycosylation is disrupted. The University of Maine System, through its Research & Sponsored Program division, will use a zebrafish model to study how loss of the dolichylphosphate mannose...
- This $820,142 Project Grant was awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research (CFDA 93.846) program. The grant aims to investigate the effects of early-life physical inactivity in mice on muscle quality, function, and frailty development in adulthood. Specifically, the research will examine the regulatory aspects of the extracellular matrix, muscle macrophages, and physical...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $198,263 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846) to the Board of Regents of the University of Nebraska. The research project aims to investigate the role of the protein Mitsugumin 53 (MG53) in preventing muscle atrophy during periods of disuse, which can contribute to age-related sarcopenia and frailty. The research will explore how...
- This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $352,777 to support research into the regulation of sarcomere growth in skeletal muscle. The research aims to: 1) Identify molecular targets that impact sarcomere addition during muscle growth, and 2) Use in vivo protein tagging methods to study the dynamics of newly synthesized sarcomere...
- This $488,575 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support research to understand how myosin binding protein-C (MYBP-C) regulates skeletal muscle contraction and how mutations in the genes encoding slow and fast MYBP-C (MYBPC1 and MYBPC2) cause congenital skeletal muscle diseases. The research team at the University of Arizona will use...
- This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846), provides $1,622,775.00 to the Van Andel Research Institute (VAI) in Grand Rapids, Michigan to study the critical role of mitochondrial oxidative metabolism in regulating muscle satellite cell fate and function. The research aims to definitively determine the metabolic requirements...
- This federal Project Grant award of $671,240 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research to develop enhanced dystrophin gene therapies for Duchenne muscular dystrophy (DMD). The University of Washington will conduct this research from January 2025 through December 2029. The project aims to design and test micro-, mini-, and full-length dystrophin gene...